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Aims: Infective endocarditis (IE) remained a potentially fatal disease with high rate of mortality and mor-
bidity. The epidemiology and global burden of IE are largely different between the countries. We aimed to
address the epidemiological aspects of IE in a tertiary hospital in Tehran, Iran.
Methods and Results: Between 2006–2018, all adults patients with diagnosis of IE were enrolled in the
Iranian Registry of Infective Endocarditis (IRIE). The data were analyzed using the v2, Kolmogorov–
Smirnov, andMann–Whitney U tests. Overall, 602 patients, 407 (67.6%) men, mean age 46 ± 16 years were
recruited. Positive blood culture found in 49%.The most common underlying heart diseases were:
Congenital heart diseases (CHD) particularly bicuspid aortic valves (BAV) and ventricular septal defects
(VSD) in 37%, followed by degenerative heart diseases :flail andmitral valve prolapse ( 16.3%), intravenous
drug user in 12.6%, prosthetic valves in 11.1%, previous IE (8.9%), rheumatic heart diseases (RHD) in 8.4%.
The most causative microorganisms were Staphylococcus aureus, Enterococci, coagulase-negative staphylo-
cocci and Streptococcus viridans. Cardiac or extra cardiac complications occurred in 56.6% of the patients.
Conclusions: Based on IRIE, IE occurs in the younger population in Iran with high rates of blood culture-
negative IE. RHD are not the main cause of IE in Iran, CHD including BAV and VSDs, followed by prolaptic
or flail mitral valve were the most common. These 2 groups can be considered a high-risk group for IE.
More than half of the patients with IE had cardiac or extra cardiac complications.
 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Infective endocarditis (IE) is a relatively rare and potentially fatal
disease despite notable advances inmedical and surgical treatment.
Thepatterns of the disease in termsof its epidemiology, pathological
basis, and antibiotic era vary considerably. The annual global inci-
dence of IE has been estimated to be 3 to 10 per 100,000 people
[1–3], similar in low-income and industrialized countries [4]. How-
ever,whereas rheumatic heart diseases (RHDs) have been suggested
as the main key risk factor for IE in developing countries [5–7],degenerative valve diseases, prosthetic valves, intracardiac devices,
and malignancies are increasingly associated with IE in developed
countries [8]. Moreover, recent decades have witnessed a shift in
the incidence of IE, from young adults to the elderly, reflectingmed-
ical and care advances in the control and prevention of IE [9].
The results of epidemiological studies vary with respect to the
microbial pathogenicity of IE. Although the type of pathogen has
not substantially changed over time—with Streptococcus, Staphylo-
coccus and Enterococcus still accounting for more than 80% of all
cases—the specific subtypes of microorganisms require a reparti-
tion of groups most at risk [10,11]. In conjunction with these
issues, even with notable advances in diagnostic technology,
improvements in antimicrobial selection, and formulation of new
guidelines for the proper management of IE, the morbidity and
mortality of the disease remain high inasmuch as 1 in 5 patients
die during the initial hospital admission, which can be due to
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the changes in the population at risk of developing IE [12–14].
The considerable variations in the epidemiology, underlying
heart diseases, pathogenic sources, and risk and prognostic factors
of IE render the prompt identification of the clinical and epidemi-
ological aspects of the disease with a view to devising the optimal
management strategy and preventing the adverse consequences in
any given society essential. Such assessment assumes even more
significance in the context of countries like Iran, where there is a
dearth of up-to-the-minute data in the face of evidence for signif-
icant changing patterns of IE [15,16].
Indeed, our exhaustive literature search of credible sources by
employingmainkeywordsyieldedvery little informationon theepi-
demiological aspects of IE in our population. Hence, in the present
study, conducted in a tertiary referral center, we sought to address
the epidemiological aspects of IE vis-à-vis its etiology, underlying
heart diseases, principal microbial pathogens, and prognosis.Fig. 1. Enrollment protocol of patients with definite or possible infective
endocarditis.2. Methods
2.1. Population
Between 2006 and 2018, all adult patients with a possible or
definite diagnosis of IE based on the modified Duke criteria were
enrolled in the Iranian Registry of Infective Endocarditis (IRIE) by
an expert team.
Twogroupsof patientswithin 2 timeperiodswere enrolled in the
present study. Between 2006 and 2016, the medical records of 900
patients admitted to our tertiary referral center with a diagnosis of
IE were reviewed. The exclusion criteria were comprised of age
younger than 18 years, outpatient status, subsequent ruling-out of
the IE diagnosis, and incomplete treatment. A total of 455 patients
were, accordingly, excluded from the study and thereafter a retro-
spective review was conducted on 445 patients with a definite or
possible diagnosis of IE. Afterward, between January 2016 and
2018, another 157 patients were prospectively enrolled (Fig. 1).
This study was approved by our local ethical committee accord-
ing to the Helsinki Declaration of the World Medical Association
(2000). All patients were informed and gave written consent before
the study.
2.2. IE diagnosis
The diagnostic criteria for IE were based on the modified Duke
criteria, requiring confirmation by pathology of the presence of
vegetation or intracardiac abscesses and fulfillment of clinical cri-
teria: 2 major, or 1 major plus 3 minor, or 5 minor criteria.
2.3. Blood culture
Blood samples for culture were drawn under sterile conditions
and processed using BD BACTECTM Blood Culture Media (Becton,
Dickinson and Company, Franklin Lakes, NJ, USA). For each patient,
the number of cultures, the positive or negative status of the cul-
ture, and the causative microorganism were recorded.
2.4. Echocardiographic assessment
The patients underwent transthoracic and transesophageal
echocardiographic examinations for an assessment of the site
and size of the vegetation, the extension of the abscess, and the
leaflet movement.
2.5. Study variables and endpoints
The study population’s demographic characteristics; history of
cardiac diseases; history of IE; signs and symptoms; sites of infec-
tion; causative microorganisms; surgical treatments; antibiotictherapies; outcomes; complications; and clinical, laboratory, and
echocardiographic features were recorded.
Complications including embolic events (systemic or cerebral),
heart failure, mycotic aneurysms, prosthetic valve dysfunction,
acute renal failure, increasing vegetation size or new abscesses,
septic shock, and persistent fever (>7 d) were recorded
The duration of follow-up was defined as the interval from the
first day of hospitalization to the day of death or, if alive, up to the
discharge day.
2.6. Statistics
The statistical analyses were performed with the SPSS software,
version 16, for Windows (SPSS Inc, Chicago, Illinois). The results are
presented as the mean ± the standard deviation (SD) for the quan-
titative variables and summarized by absolute frequencies and
percentages for the categorical variables.
The one-sample Kolmogorov–Smirnov test was used to evaluate
the distribution of the data, and the independent t-test or theMann–
Whitney U test was applied to compare the mean of the variables
between the 2 groups. The qualitative data were compared using
thev2 test or the Kruskal–Wallis test (ordinal variables). The logistic
regressionmodelwas applied formultivariable analysis. A P value of
less than 0.05 was considered statistically significant.
3. Results
The study population consisted of 602 patients, including 407
(67.6%)men, at amean age of 46 ± 16.8 years. Based on themodified
Duke criteria, 400 (66.4%) patients had definite and 202 (33.6%) had
possible IE. Left-sided IE was reported in 535 patients: native valve
Fig. 2. Underlying heart disease in patients with infective endocarditis.
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Right-sided IE was reported in 266 patients: native endocarditis in
245 (40.7%) and right-sided prosthetic endocarditis in 21 (3.5%).
3.1. Predisposing factors and symptoms
The study population’s baseline characteristics, predisposing
factors, signs and symptoms, and clinical examination and labora-
tory findings on admission are depicted in Table 1.
The most common underlying heart diseases for IE were CHDs
(37%) and specifically, bicuspid aortic valves (BAVs) and ventricu-
lar septal defects (VSDs). Degenerative heart diseases (16.3%),
including flail mitral valves and mitral valve prolapse (MVP), com-
prised the second most frequent underlying heart diseases for IE. In
addition, intravenous drug use (12%), prosthetic valves (11%), pre-
vious IE (8%), RHDs (8%), and device-related IE (6%) accounted for
the other predisposing factors for IE development (Fig. 2).
The most common chief complaint was fever (92%); addition-
ally, cardiac murmurs were detected in 80% of the patients, loss
of appetite in 25%, and splenomegaly in 24% (Table 1).
Themeanofwhite blood cell (WBC)was 10269 ± 47, hemoglobin
10.3 ± 2, erythrocyte sedimentation rate was 56.4 ± 30, and the
meanC-reactive protein levelwas 41.6 ± 48.3. An increased erythro-
cyte sedimentation rate (>20) was reported in 381 (63.3%) patients,
an increased C-reactive protein level (>3) in 285 (47.3%), and a
hemoglobin level of less than 12 g/100 mL in 473 (78.7%).
3.2. Causative microorganisms of IE
Two or more positive blood cultures with the same microorgan-
ism were reported in 296 (49%) patients. The most frequently iso-
lated microorganism in the blood cultures was Staphylococcus
aureus (S. aureus) (10%), followed by enterococci (9%), coagulase-
negative staphylococci (8%), and Streptococcus viridans (S. viridans)
(6%). S. aureus, enterococci, and coagulase-negative staphylococci
were more prevalent in the patients with native valve endocarditis
(including RHDs and degenerative heart diseases), but S. viridans
was the leading cause of IE in those with CHDs.
Surgical interventions including valve replacement, residual
defect repair, tricuspid valve excision without replacement, lead
extraction, and large vegetation extraction were performed on
345 (57%) patients. The mean vegetation size was 3.12 ± 1.5 cm,
and the most frequent sites of vegetation were the mitral valve
(251 cases), the aortic valve (251 cases), the tricuspid valve (114
cases), and the pulmonary valve (22 cases).
Cardiac or extra-cardiac complications occurred in 56.6% of the
study patients. Among the cardiac complications, heart failure was
the most common (7%), followed by new abscesses (6%) and
mitral-aortic intervalvular fibrosa pseudoaneurysms.
There was a significant relationship between the IE cardiac
complications and S. viridans (P = 0.04), Pseudomonas (P = 0.03),
and Serratia marcescens (P = 0.005). A significant relationship alsoTable 1
Predisposing factors, symptom and clinical examination and laboratory findings of
patients with Infective Endocarditis.
Patients with IE (n = 602)
Predisposing factors
Congenital heart disease 223(37%)
Degenerative heart disease 98(16.3%)
Intravenous drug user 76(12.6%)
Prosthetic valve 67(11.1%)
Previous infective endocarditis 54(8.9%)
Chronic rheumatic heart disease 51(8.4%)
Device related IE 36(6.1%)
Symptoms and clinical examination
Fever (chief complaint) 553(91.9%)
Cardiac Murmur 484(80.4%)
Loss of appetite 151(25.1%)
Splenomegaly 107(24.0%)existed between the extra-cardiac complications of IE and S. aureus
(P = 0.005), enterococci (P = 0.05), Klebsiella (P = 0.01), and S. sapro-
phyticus (P = 0.01).
In-hospital mortality occurred in 109 (18%) patients, 45 of
whom had surgical interventions. The relationship between mor-
tality and surgical interventions was statistically significant in that
the mortality rate was lower among the patients who underwent
surgical interventions (63 patients with no surgery vs 45 patients
with surgery) (P < 0.001).
In the multivariate analysis, the independent risk factors for
mortality in the study population were age (95% CI: 1.004–1.048,
P = 0.02) and S. aureus (95% CI: 1.973–11.187, P < 0.001).
A lower mortality rate in the study population was associated
with S. viridans, degenerative heart diseases, CHDs, and cardiac sur-
gical interventions (Table 2).
4. Discussion
The IRIE is the largest case-series study of patients with IE in
Middle-Eastern countries (16).
The main findings of our study can be summarized as follows:
1. CHDs are the most common underlying heart diseases (37%) in
patients presenting with IE in Iran.
2. Themost frequent predisposing factors andunderlyingheart dis-
eases for IE are CHDs (37%) and in particular, BAVs and VSDs.
Degenerative heart diseases (16.3%), including flail mitral valves
and MVP, comprise the second most common underlying heart
diseases for IE. These 2 groups can be considered a high-risk
group for IE. Ourfindings are contrary topreviously reporteddata
in developing countries identifying RHDs as themain cause of IE.
3. IE in Iran has a male predominance and occurs at a young age
(mean age = 45 y), when the individual is expected to be at peak
physical activity. Further, IE can cause highmorbidity andmortal-
itybearing inmind thatmore than50%of patientswith IE are liable
to develop one form of cardiac or extra-cardiac complication.
4. Our data indicate a high burden of IE on community resources.
More than half of our patients needed surgical interventions,
along with prolonged hospitalization lengths and intensified
needs for extensive antibiotic therapy and intensive care.
5. We found a high rate of blood culture-negative IE insofar as
only 49% of our patients had typical positive blood cultures.
6. Despite diagnostic and therapeutic advances, IE continues to
cause high mortality (18% in-hospital mortality) and morbidity
rates. More than half of our patients with IE had cardiac or
extra-cardiac complications.
Table 2
Baseline characteristics, predisposing factors, and clinical and laboratory findings of IE patients who died and those who survived.
Univariate analysis Multivariate analysis
Dead Survived p-value Odds ratio (CI95%) p-value
Age 54.90 ± 17.99 44.08 ± 15.90 P < 0.001 1.026 (1.004–1.048) 0.02
Sex (male) 72(66.1) 335(68) 0.70
Device related IE 8(7.5) 28(5.8) 0.50
Intravenous drug abuser 9(8.3) 67(13.6) 0.12
Degenerative heart disease 10(9.2) 88(17.8) 0.02 0.884 (0.301–2.616) 0.82
Congenital heart disease 18(16.5) 208(41.6) >0.001 0.987 (0.376–2.587) 0.97
Causative germ
Staphylococcus aureus 25(22.9) 38(7.7) >0.001 4.698 (1.97–11.18) >0.001
Enterococci 13(11.9) 43(8.7) 0.29
Coagulase negative staphylococci 15(13.8) 31(6.3) 0.008 1.723 (0.458–6.482) 0.42
Streplococcus viridans 0(0) 39(7.9) 0.002 0.001 (0.0001–0.009) 0.99
Cardiac surgical intervention 46 (42.2) 299(60.8) >0.001 0.589 (0.290–1.195) 0.14
Cerebral embolic events on admission 36(39.6) 79(19.3) >0.001 1.223 (0.570–2.622) 0.60
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patients with IE, many studies have reported large epidemiological
differences between the continents and even within a continent.
The mean age of our patients was 45 years, which is very close to
the mean age of 47 years among the patients in a study on IE in
Turkey. The age of our study population is significantly lower than
the pooled mean age for the occurrence of the disease reported in a
systematic review of 160 studies on the epidemiological aspects of
IE in 2013 (57.2 y) [17].
The existing literature contains a considerable number of studies
on IE; still, there are remarkable differences between the studies con-
cerning not only the underlying heart diseases but also the epidemi-
ological, microbiological, and prognostic aspects of IE in each
population. These disparities exist both between developed and
developing countries and between Mediterranean and Middle East-
ern countries. RHDs, suggestedas the chief culprit for IE indeveloping
countries, were not the main underlying heart disease in our study.
Indeed, only 8.4% of our patients with IE suffered fromRHDs, making
themthe sixthmostcommonunderlyingcardiacdisease inour study.
A recent study compared epidemiological data on IE in Mediter-
ranean countries and reported remarkable differences with respect
to the patients’ age, causative microorganisms, and underlying
heart diseases between these countries. Based on the classification
in that study, patients with IE in northern Mediterranean countries
were old (>50 y), S. aureus was the main causative microorganism,
and prosthetic valves or intracardiac implanted devices were the
major predisposing factors. Additionally, patients with IE in south-
ern Mediterranean countries were young (<40 y), S. viridans was
the prevalent etiological agent, and RHDs constituted the principal
risk factors. Moreover, patients with IE in eastern Mediterranean
countries were aged between 45 and 60 years, S. viridans was the
main causative microorganism, and the incidence of RHDs varied
between 8% and 66% [16,18].
One of the most interesting findings in the IRIE was the preva-
lence of the underlying heart diseases in the patients with IE insofar
as CHDs (including BAVs and VSDs) and degenerative heart diseases
(includingMVP) accounted formore than half of the underlying car-
diac diseases and were, thus, the major risk factors for IE. S. viridans
was the leading cause of IE in the patients suffering from CHDs. Our
data chime in with recently published data by Zhu and Zegri-Reiriz,
who underlined the changing epidemiology and dominance of BAVs
andMVP as the common cause of IE andflagged up BAVs andMVP as
high-risk conditions for IE. ZhuandZegri-Reiriz, having foundhigher
rates of S. viridans in their patients with BAVs and MVP, recom-
mended IE antibiotic prophylaxis.
BAVs and MVP, with corresponding prevalence rates of 1–2%
and 2.0–3.0%, comprise the most common form of congenital car-
diac abnormities and the most frequent predisposing cardiac con-
ditions for IE in some countries, including Iran [16,19–23].
Unrepaired VSDs are another frequent congenital heart abnor-
mality associated with IE. The overall incidence of IE in cases with
unrepaired VSDs has been estimated to range between 1.5 and 2.4per 1000 patient-years. The natural history of VSDs shows that the
estimated lifetime risk for IE is 9.7% at age 30 years and 12% by the
end of life [24–26].
We found that the frequency of causative microorganisms dif-
fered in tandem with the underlying heart disease. According to
the IRIE, the most prevalent etiological agent was S. aureus (10%),
followed by enterococci (9%), coagulase-negative staphylococci
(8%), and S. viridans (6%).
S. aureus occurs predominantly in community-acquired and
nosocomial cases of IE, as has been reported by recent series
[10,11,27,28], whereas S. viridans was the prevailing etiological
agent in previous decades and also in a few recent studies. What
is deserving of special note, however, is that the causative microor-
ganism is likely to differ based on the epidemiology of the country
and the underlying heart diseases [6,29–31].
Our results showed an association between IE and high
mortality (18% in-hospitalmortality) andmorbidity rates in Iran. Fur-
thermore, the patients with IE who underwent surgical
interventions had a lower mortality rate than their counterparts
whodidnot,which is consistentwithotherpublishedstudies [32,33].
In respect of microbiological assessment, typical positive blood
cultures were reported in 49% of the patients registered in the IRIE.
According to a review of the literature published in developed coun-
tries, the presence of a positive blood culture varied from83% to 96%
[34–37]. Indeed, the high rate of blood culture-negative IE (no cau-
sative microorganism can be grown using the usual blood culture)
in our study (51%) by comparison with the rates of 10–30% of blood
culture-negative IE in the European studies and other centers stud-
ies make difficulties in antibiotic therapy. The diminished culture
positivity rate in thecurrent studycanbeexplainedpartlyby the fact
that our tertiary referral hospital admits patients having already
been placed on antibiotic treatment by peripheral hospitals.
4.1. Limitation
Our data gathering was heterogeneous on account of the fact
that the information was obtained from medical records before
the IRIE was established and the local data were prospectively
obtained. Consistency was ensured through the use of similar data
sheets for the comparison of the retrospective and prospective
data. As contributors to the EURO-ENDO Registry, we received
good feedback on data entering. The present study does not pre-
sent data on the midterm follow-up and mortality of our patients;
these data will, however, be presently published as a part of the
EURO-ENDO Registry [38].5. Conclusions
According to the IRIE, IE occurs in the younger population in
Iran (mean age = 45 y) with high rates of blood culture-negative
IE and different underlying heart diseases. CHDs (37%), including
A. Sadeghpour et al. / IJC Heart & Vasculature 26 (2020) 100433 5BAVs and VSDs, followed by degenerative heart diseases (16.3%),
including flail mitral valves and MVP, were the most common
underlying heart diseases. These 2 groups can be considered a
high-risk group for IE and in need of IE prophylaxis. More than half
of our patients with IE had cardiac or extra-cardiac complications.
The IRIE showed that in addition to the need for adherence to the
European and American guidelines, the preventive and treatment
policies for IE should be redefined in each country.
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